CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • FDA Approves Blood Test to Screen for Colon Cancer

    People living with colorectal cancer, their families, caregivers, and doctors were given a glimmer of hope on…
    August 2, 2024| Max Mallet
  • Why You Should Leave CRI in Your Will

    There are many distinct ways to generously give to the Cancer Research Institute (CRI) and help propel…
    July 31, 2024| Max Mallet
  • Omar Ghaffar Breaks Golf World Record and Raises Over $20,000 for CRI

    Illinois-based Omar Ghaffar loves golf and is passionate about raising awareness and supporting CRI’s mission. In the…
    July 18, 2024| Cierra Howard
  • UV Safety Awareness Month: Why the Future is Bright for Melanoma Immunotherapies

    As the summer peaks and people around the U.S. and the world spend more time outside to…
    July 17, 2024| Max Mallet
  • Immune Cell Triads Unveil a Critical Role in Fighting Solid Tumors

    The Cancer Research Institute (CRI) is excited to share the latest study from CRI Lloyd J. Old…
    July 17, 2024| Ajit Muley, PhD
  • July is Sarcoma Awareness Month – Here’s What You Need to Know

    Sarcomas are a complex type of cancer that can trick the body into thinking the tumor is…
    July 9, 2024| Max Mallet
  • 10 Attractions to Visit in and around Washington, D.C. While Attending CICON24 

    The eighth annual CRI-ENCI Cancer Immunotherapy Conference (CICON24) kicks off on September 8 in National Harbor, Maryland….
    July 2, 2024| Max Mallet
  • Journey Through the Highlights of the 12th Annual Cancer Immunotherapy Month™ 

    Each June, CRI invites its global community of scientists, caretakers, patients, and more to take part in…
    July 1, 2024| Max Mallet
  • FDA approves EPKINLY® for relapsed or refractory follicular lymphoma

    June 26, 2024, marked a milestone for patients suffering from follicular lymphoma. The FDA approved Genmab’s epcoritamab-bysp…
    June 28, 2024| Ajit Muley, PhD
Previous Page
1 … 6 7 8 9 10 … 91
Next Page
Father and son

Join CRI in Shaping the Future of Immunotherapy

Support the pioneering work of CRI in advancing immunotherapy.

See ways to give

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute